Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dengue Shock Syndrome Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

NCT00473135
View directory record Official record
Conditions
Dengue
Interventions
rDEN1delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 21, 2026, 6:12 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection

NCT07706686
View directory record Official record
Conditions
Healthy Volunteers, Dengue, Human Challenge Trial
Interventions
rDEN2delta30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

NCT01488890
View directory record Official record
Conditions
Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
Interventions
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
7
States / cities
Alabaster, Alabama • Sacramento, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

NCT01943825
View directory record Official record
Conditions
Dengue, Dengue Fever, Dengue Hemorrhagic Fever
Interventions
CYD Dengue Vaccine, Japanese Encephalitis Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

NCT01666652
View directory record Official record
Conditions
Dengue Fever
Interventions
4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01072786
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine-Admixture 1, TetraVax-DV Vaccine-Admixture 2, TetraVax-DV Vaccine-Admixture 3, TetraVax-DV Vaccine-Admixture 4, Placebo, TetraVax-DV Vaccine-Admixture 5
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

NCT01073306
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for Dengue Virus Subtype 2, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults

NCT00094705
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN2/4delta30(ME) Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults

NCT00270699
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN4delta30-200,201, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

NCT00617344
View directory record Official record
Conditions
Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
Interventions
Tetravalent CYD Dengue Vaccine , 5555 formulation, Tetravalent CYD Dengue Vaccine , 5553 formulation, Tetravalent CYD Dengue Vaccine, 4444 formulation
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
5
States / cities
Hoover, Alabama • San Diego, California • Vallejo, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus

NCT00919178
View directory record Official record
Conditions
Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Interventions
DEN4 Vaccine Candidate, DEN4 Vaccine Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults

NCT00831012
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN3delta30/31-7164
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

NCT00458120
View directory record Official record
Conditions
Dengue Hemorrhagic Fever
Interventions
rDEN1delta30, rDEN2/4delta30(ME), Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2010 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults

NCT00322946
View directory record Official record
Conditions
Dengue
Interventions
rDEN4delta30-4995, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults

NCT00089908
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN1delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2008 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01436422
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

NCT02392325
View directory record Official record
Conditions
Dengue
Interventions
rDEN1Δ30, Placebo, rDEN2Δ30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of HBV-001 D1 in Healthy Adults

NCT00936429
View directory record Official record
Conditions
Dengue Fever
Interventions
DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel), Placebo for DEN1-80E
Biological
Lead sponsor
Hawaii Biotech, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 6, 2011 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine

NCT01084291
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for DEN1, Placebo injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 21, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults

NCT00375726
View directory record Official record
Conditions
Dengue
Interventions
rDEN3/4delta30(ME), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2010 · Synced Jul 21, 2026, 6:12 PM EDT